Orion and Selvita to develop treatment for Alzheimer's disease
This article was originally published in Scrip
Executive Summary
Finland's Orion and Poland's Selvita have started a joint project to develop and commercialise SEL103, the Krakow-based company's proprietary programme for the treatment of Alzheimer's disease and other cognitive disorders. Selvita said that the programme involved selective small molecules.